Company intelligence / Profile preview

Corvention

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Corvention was a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiovascular and renal diseases. The company's lead program, CVN058, is a potent and selective non-steroidal mineralocorticoid receptor antagonist (nsMRA) designed to treat heart failure and chronic kidney disease with a reduced risk of hyperkalemia compared to traditional steroidal MRAs. Corvention was established as a portfolio company of Deerfield Management to advance cardiovascular assets. The company was eventually acquired by AstraZeneca to bolster its late-stage cardiovascular and renal pipeline.

Therapeutic areas: CardiovascularNephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Corvention.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corvention.

Explore the full profile